流感病毒抑制剂的研究进展  

Research Progress on Inhibitors of Influenza Viruses

作　　者：邵亮 俞飞 SHAO Liang;YU Fei(Kunming University of Science and Technology,Kunming 650500,China)

机构地区：[1]昆明理工大学医学院,昆明650500

出　　处：《病毒学报》2021年第5期1187-1196,共10页Chinese Journal of Virology

基　　金：云南省科技厅科技计划项目(项目号:2019FB125),题目:齐墩果酸三聚体作为流感病毒进入抑制剂的构效关系及分子机制研究。

摘　　要：流感病毒(Influenza Virus,IVs)属于正黏病毒科(Orthomyxoviridae),单股负链RNA包膜病毒,由于其传播和变异速度快,且致病力和致死率高,严重威胁人类的健康和生命。理论上,抑制流感病毒生命周期的任何一个阶段,都可以有效地抑制病毒的复制和传播。目前FDA已批准的药物主要作用于子代病毒的释放阶段,随着流感病毒耐药问题的日益严重,不同作用机制的抑制剂不断被发现,部分已经进入临床研究阶段。新技术、新思路持续推进着流感病毒抑制剂的研究,本文将对最新的流感病毒抑制剂研究进展进行综述,旨在为新型的流感病毒抑制剂的设计和研发提供参考和思路。Influenza viruses(IVs)belong to the Orthomyxoviridae family.They are negative⁃sense and single⁃stranded RNA viruses.Due to their high mutation rate,IVs are major threats to humans.Theoretically,inhibition of any stage of the life cycle of IVs can block their replication and spread.Currently,drugs approved by US Food and Drug Administration used against IVs mainly target viral release.To deal with the continuous emergence of IV⁃resistant strains,different inhibitors with novel mechanisms have been discovered,some of which are in different phases of clinical trials.Here,we review recent research progress on IV inhibitors to provide references and concepts for design and development of new anti⁃influenza drugs.

关 键 词：流感病毒(IVs) 抑制剂 小分子 药物靶标 

分 类 号：R373.13[医药卫生—病原生物学]